SCHEMBL8932766

SCHEMBL8932766

O=C1NC(=S)SC1Cc1c[nH]c2ccccc12

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.60
CA2 P00918 2/20 0.58
MAPT P10636 4/20 0.50
CYP3A4 P08684 3/20 0.50
TP53 P04637 1/20 0.50
GLA P06280 1/20 0.50
THRB P10828 1/20 0.50
RIPK1 Q13546 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KMT2A Q03164 5/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
POLB P06746 1/20 0.48
HPGD P15428 1/20 0.48
SLC6A4 P31645 1/20 0.47
CCKBR P32239 3/20 0.46
MEN1 O00255 4/20 0.46
GSK3B P49841 2/20 0.46
AHR P35869 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29764730 1.00 IDO1 (0.60) IDO1CA2MAPTCYP3A4TP53
SCHEMBL8932687 0.87 IDO1 (0.54) IDO1MAPTCYP3A4TP53GLA
SCHEMBL29764702 0.82 HTR6 (0.50) IDO1CA2MAPTCYP3A4TP53
SCHEMBL29764657 0.82 CA2 (0.47) IDO1CA2MAPTCYP3A4TP53
SCHEMBL23579169 0.81 GPR84 (0.50) IDO1CA2KMT2AGSK3BGPR84
SCHEMBL8173384 0.80 CA2 (0.57) IDO1CA2MAPTKMT2AKDM4E
SCHEMBL29764682 0.79 CA2 (0.50) IDO1CA2SMN1; SMN2CCKBRGSK3B
SCHEMBL23578853 0.77 CA2 (0.57) IDO1CA2MAPTSMN1; SMN2KMT2A
SCHEMBL8192792 0.75 NPC1 (0.57) CA2SMN1; SMN2HSD17B10KMT2AKDM4E
SCHEMBL25366253 0.75 IDO1 (1.00) IDO1MAPTCYP3A4TP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) 2023-04-27 US disclosed
WO-1996026207-A1 THIAZOLIDINE AND OXAZOLIDINE INDOLES WITH HYPOCLYCEMIC ACTIVITY NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 1996-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129364-A1 PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME MAPT, APP, PRNP IDO1 3016/4885CA2 3114/4885MAPT 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.